Suven Life Science jumped 4.78% to Rs 66.90 after the company announced that its board will consider a rights issue of shares on 24 June 2022.
The company plans to raise funds through issue of equity shares of the company on rights basis to the existing equity shareholders of the company.The board will also discuss other matters related/ incidental thereto including the constitution of a committee of board of directors namely 'Rights Issue Committee' to implement the proposal of rights issue.
Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
On consolidated basis, the pharmaceutical company reported a net loss of Rs 20.80 crore as against a net loss of Rs 21.61 crore in Q4 FY22 over Q4 FY21. Net sales jumped 170.5% YoY to Rs 4.22 crore during the quarter.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app